ALVO Alvotech

BUSINESS SUMMARY

Alvotech is an Iceland-based biosimilars-and-related-biologics company with a vertically-integrated biopharmaceutical platform — the company develops, manufactures, and supplies biosimilar versions of complex biological drugs whose patents have expired or are nearing expiration.

The strategic-anchor product is the AVT02 (adalimumab biosimilar) — Simlandi — a high-concentration, citrate-free biosimilar of AbbVie's Humira, the world's best-selling drug for over a decade until biosimilar entry began in 2023. Alvotech's adalimumab biosimilar is differentiated by its high-concentration formulation that matches the originator's most-prescribed format.

The pipeline includes biosimilars of Stelara (ustekinumab), Eylea (aflibercept), Prolia/Xgeva (denosumab), and other large-revenue biological drugs. Alvotech's commercial model varies by geography — direct distribution in some markets, partnerships (Teva in the US, Stada in Europe) in others.

MARKET OPPORTUNITY

The biosimilar market opportunity is structurally large but timing-and-execution dependent:

• Adalimumab biosimilar market — Humira's annual revenue peaked at ~$20B; biosimilar penetration in the US has been slower than expected but is accelerating
• Stelara biosimilar opportunity — Stelara generated ~$10B annual revenue at peak; biosimilar entry in 2025 is the next major commercial event
• Eylea biosimilar opportunity — large ophthalmology market with biosimilar potential
• Multi-pipeline-asset development — several biosimilars in clinical-and-regulatory pipeline beyond the lead products

Macro context: revenue growth of 20% YoY reflects continued biosimilar adoption combined with Stelara biosimilar launch contribution as that opportunity opens.

REVENUE QUALITY

The economics reflect a vertically-integrated biopharmaceutical company:

• Gross margin 60% — moderate-to-high; reflects the vertical-integration manufacturing economics versus contract-manufacturing models
• Operating margin — improving as the multi-product portfolio absorbs fixed manufacturing costs
• Revenue $586M TTM — meaningful scale
• P/S ~1.9 — reasonable for the biosimilar-pipeline-with-execution-risk profile

COMPETITIVE ADVANTAGE

The defensible asset is the vertically-integrated manufacturing platform plus the biosimilar-pipeline development capability:

• Vertical integration — Alvotech operates its own manufacturing rather than relying on contract-manufacturing-organizations, providing supply-chain control and unit-cost advantage
• Biosimilar-development pipeline — multiple biosimilars in concurrent development represents real platform optionality versus single-product peers
• High-concentration formulation expertise — the adalimumab biosimilar's formulation matches the originator's preferred format, important for commercial uptake

What it is not: a moat against the larger biosimilar players (Sandoz, Samsung Biologics, Coherus, Celltrion, Amgen) at scaled-pipeline level. Alvotech competes on vertical-integration and pipeline-execution.

GROWTH THESIS

Three things have to work:

1. Stelara biosimilar (AVT04) commercial launch executes. This is the multi-quarter near-term value driver as Stelara's $10B+ revenue base opens to biosimilar entry.
2. Adalimumab biosimilar penetration continues. US biosimilar uptake has been slow but accelerating; continued share-take supports the existing-product revenue line.
3. Pipeline-asset advancement. Eylea, Prolia, and other biosimilars in pipeline need to advance toward commercial launches.

KEY RISKS

Three specific risks:

1. Manufacturing-execution risk. Biological-drug manufacturing is technically demanding; an FDA inspection finding or supply-chain interruption is materially disruptive at this scale.

2. Originator-litigation pressure. Originator-pharmaceutical companies (AbbVie, J&J, Regeneron, Amgen) actively litigate biosimilar entrants. Patent-litigation outcomes affect commercial timelines.

3. PBM and payer formulary decisions. Biosimilar uptake depends heavily on PBM and Medicare formulary placements; unfavorable formulary decisions compress revenue without operational change.

VERDICT

The 80.3/100 score captures genuine biosimilar-platform quality combined with the multi-pipeline-asset development optionality. The valuation reflects the biosimilar-execution-risk premium plus the manufacturing-and-litigation-overhang pricing.

For investors who want biosimilar-platform exposure outside the larger players (Sandoz, Samsung Biologics) and with vertical-integration economics, ALVO is one of few liquid mid-cap pure-plays. For investors needing scale or wanting to avoid biosimilar-execution-and-litigation complexity, the structural risks are disqualifying.

The single metric to watch next is AVT04 (Stelara biosimilar) launch trajectory. Successful Stelara biosimilar penetration is the multi-year value driver that separates Alvotech from a single-asset biosimilar peer.